Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 earnings results
Supernus Pharmaceuticals, Inc. (SUPN) reported Q3 2026 results on Oct 29, 2026, 4:08:49 PM ET: GAAP EPS $0.35 vs. $0.49 expected (miss by 28.6%); revenue $226.80M vs. $217.56M expected (beat by 4.2%). Outlook: The company raised its full year 2026 revenue guidance to $875 million - $900 million.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | $0.35 | $0.49 | Miss by 28.6% |
| Revenue | $226.80M | $217.56M | Beat by 4.2% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Oct 29, 2026, 4:08:49 PM ET. Nexqual published them 2 min 29 s after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 18.1% from $192.10M; GAAP diluted EPS was $0.35 vs. -$0.80.
Stock reaction
The results came out after the market closed. SUPN closed at $41.84 on October 29, 2026, before the results. The first trading session after the release is Friday, October 30, 2026; this page shows the reaction once trading starts (pre-market and after-hours prices are not included).
Questions and answers
Did Supernus Pharmaceuticals, Inc. beat earnings expectations?
No. Supernus Pharmaceuticals, Inc. reported GAAP EPS of $0.35 against an average analyst estimate of $0.49 (miss by 28.6%), and revenue of $226.80M against $217.56M expected (beat by 4.2%).
What were Supernus Pharmaceuticals, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of $0.35 and revenue of $226.80M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 18.1% from $192.10M; GAAP diluted EPS was $0.35 vs. -$0.80.
When did Supernus Pharmaceuticals, Inc. report Q3 2026 earnings?
Oct 29, 2026, 4:08:49 PM ET, in an SEC 8-K filing (Item 2.02).
How did SUPN stock react to the earnings?
The results came out after the market closed. SUPN closed at $41.84 on October 29, 2026, before the results. The first trading session after the release is Friday, October 30, 2026; this page shows the reaction once trading starts (pre-market and after-hours prices are not included).
What did Supernus Pharmaceuticals, Inc. say about its outlook?
The company raised its full year 2026 revenue guidance to $875 million - $900 million.
More on SUPN
SUPN stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings October 29, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built October 29, 2026 at 23:08 UTC. Not investment advice.
Data source: Nexqual. Last updated: October 29, 2026 at 23:08 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt